Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3%

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 273,800 shares, an increase of 691.3% from the August 31st total of 34,600 shares. Currently, 11.2% of the company’s stock are short sold. Based on an average daily trading volume, of 3,610,000 shares, the short-interest ratio is currently 0.1 days.

SciSparc Price Performance

SPRC traded down $0.01 during trading hours on Wednesday, hitting $0.25. 261,813 shares of the company’s stock were exchanged, compared to its average volume of 1,761,522. SciSparc has a 12-month low of $0.24 and a 12-month high of $14.22. The firm has a 50 day moving average of $0.39 and a 200 day moving average of $1.00.

Institutional Investors Weigh In On SciSparc

A hedge fund recently bought a new stake in SciSparc stock. Renaissance Technologies LLC acquired a new stake in SciSparc Ltd. (NASDAQ:SPRC) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned about 5.59% of SciSparc at the end of the most recent quarter. Institutional investors own 25.06% of the company’s stock.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.